Electroclinical Findings of SYNJ1 Epileptic Encephalopathy

Debopam Samanta1, Kapil Arya1

  • 1Child Neurology Section, Department of Pediatrics, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.

Insights

A novel genetic cause of early-onset epileptic encephalopathy was identified in a Saudi Arabian infant with severe epilepsy. This discovery highlights the role of SYNJ1 gene variants in progressive neurodegeneration and intractable seizures.

Area of Science:

  • Neuroscience
  • Genetics
  • Pediatric Neurology

Background:

  • Early-onset epileptic encephalopathies (EOEEs) are severe epilepsy syndromes causing progressive neurodegeneration.
  • Identifying novel genetic causes is crucial for understanding EOEE etiology.

Observation:

  • A Semitic (Saudi Arabian) infant presented with multifocal seizures, progressing to intractable infantile spasms and myoclonic seizures.
  • Clinical and electroencephalographic findings were consistent with EOEE.
  • Whole exome sequencing revealed a homozygous novel pathogenic variant (p.Q287PfsX27) in the SYNJ1 gene.

Findings:

  • The identified SYNJ1 variant leads to a critical reduction in dual phosphatase activity.
  • Clinical manifestations include early-onset intractable focal, myoclonic seizures, infantile spasms, hypotonia, and progressive neurodegeneration.
  • Brain MRI is typically normal, while EEG shows diffuse slowing with epileptiform discharges or modified hypsarrhythmia.

Implications:

  • This case describes a new form of EOEE linked to synaptic dysregulation.
  • It underscores the importance of the SYNJ1 gene and synaptic pathways in severe epilepsy pathophysiology.
  • Further research into SYNJ1 variants can improve diagnosis and therapeutic strategies for severe early-onset epilepsies.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.0K
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.2K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
716
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
586
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.1K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
524